Relief Therapeutics
Relief Therapeutics Holding AG is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients suffering from rare and common diseases. The company's pipeline includes both commercialized products and drug candidates in various stages of clinical development. Its lead commercial product, PKU GOLIKE®, is a prescription medical food for the dietary management of Phenylketonuria (PKU), and it also has a notable drug candidate, RLF-TD011, for the treatment of epidermolysis bullosa (EB). Relief Therapeutics aims to address unmet medical needs through strategic partnerships and a robust development pipeline.
About Us
- Relief Therapeutics Holding AG is a Swiss biopharmaceutical company that actively engages in the discovery, development, and commercialization of new therapeutic assets. - With a strong commitment to improving patient lives, Relief Therapeutics strategically builds its portfolio through internal research and development, as well as through acquisitions and partnerships. - Their focus encompasses a range of therapeutic areas, particularly rare diseases and metabolic disorders. - The company is publicly traded on the SIX Swiss Exchange and maintains an international presence through its operations and collaborations.
Specialties & Industries
Open Positions
No open positions at the moment
Check back later for new opportunities